Literature DB >> 22973033

Deletion of specific immune-modulatory genes from modified vaccinia virus Ankara-based HIV vaccines engenders improved immunogenicity in rhesus macaques.

David A Garber1, Leigh A O'Mara, Sailaja Gangadhara, Monica McQuoid, Xiugen Zhang, Rui Zheng, Kiran Gill, Meena Verma, Tianwei Yu, Brent Johnson, Bing Li, Cynthia A Derdeyn, Chris Ibegbu, John D Altman, Eric Hunter, Mark B Feinberg.   

Abstract

Modified vaccinia virus Ankara (MVA) is a safe, attenuated orthopoxvirus that is being developed as a vaccine vector but has demonstrated limited immunogenicity in several early-phase clinical trials. Our objective was to rationally improve the immunogenicity of MVA-based HIV/AIDS vaccines via the targeted deletion of specific poxvirus immune-modulatory genes. Vaccines expressing codon-optimized HIV subtype C consensus Env and Gag antigens were generated from MVA vector backbones that (i) harbor simultaneous deletions of four viral immune-modulatory genes, encoding an interleukin-18 (IL-18) binding protein, an IL-1β receptor, a dominant negative Toll/IL-1 signaling adapter, and CC-chemokine binding protein (MVAΔ4-HIV); (ii) harbor a deletion of an additional (fifth) viral gene, encoding uracil-DNA glycosylase (MVAΔ5-HIV); or (iii) represent the parental MVA backbone as a control (MVA-HIV). We performed head-to-head comparisons of the cellular and humoral immune responses that were elicited by these vectors during homologous prime-boost immunization regimens utilizing either high-dose (2 × 10(8) PFU) or low-dose (1 × 10(7) PFU) intramuscular immunization of rhesus macaques. At all time points, a majority of the HIV-specific T cell responses, elicited by all vectors, were directed against Env, rather than Gag, determinants, as previously observed with other vector systems. Both modified vectors elicited up to 6-fold-higher frequencies of HIV-specific CD8 and CD4 T cell responses and up to 25-fold-higher titers of Env (gp120)-specific binding (nonneutralizing) antibody responses that were relatively transient in nature. While the correlates of protection against HIV infection remain incompletely defined, our results indicate that the rational deletion of specific genes from MVA vectors can positively alter their cellular and humoral immunogenicity profiles in nonhuman primates.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22973033      PMCID: PMC3497691          DOI: 10.1128/JVI.00246-12

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  84 in total

1.  Safety, immunogenicity and efficacy of modified vaccinia Ankara (MVA) against Dryvax challenge in vaccinia-naïve and vaccinia-immune individuals.

Authors:  Janie Parrino; Lewis H McCurdy; Brenda D Larkin; Ingelise J Gordon; Steven E Rucker; Mary E Enama; Richard A Koup; Mario Roederer; Robert T Bailer; Zoe Moodie; Lin Gu; Lihan Yan; Barney S Graham
Journal:  Vaccine       Date:  2006-11-07       Impact factor: 3.641

2.  Phase 1 safety and immunogenicity testing of DNA and recombinant modified vaccinia Ankara vaccines expressing HIV-1 virus-like particles.

Authors:  Paul A Goepfert; Marnie L Elizaga; Alicia Sato; Li Qin; Massimo Cardinali; Christine M Hay; John Hural; Stephen C DeRosa; Olivier D DeFawe; Georgia D Tomaras; David C Montefiori; Yongxian Xu; Lilin Lai; Spyros A Kalams; Lindsey R Baden; Sharon E Frey; William A Blattner; Linda S Wyatt; Bernard Moss; Harriet L Robinson
Journal:  J Infect Dis       Date:  2011-01-31       Impact factor: 5.226

3.  Duration of humoral immunity to common viral and vaccine antigens.

Authors:  Ian J Amanna; Nichole E Carlson; Mark K Slifka
Journal:  N Engl J Med       Date:  2007-11-08       Impact factor: 91.245

4.  Replication-incompetent adenoviral vaccine vector elicits effective anti-immunodeficiency-virus immunity.

Authors:  John W Shiver; Tong-Ming Fu; Ling Chen; Danilo R Casimiro; Mary-Ellen Davies; Robert K Evans; Zhi-Qiang Zhang; Adam J Simon; Wendy L Trigona; Sheri A Dubey; Lingyi Huang; Virginia A Harris; Romnie S Long; Xiaoping Liang; Larry Handt; William A Schleif; Lan Zhu; Daniel C Freed; Natasha V Persaud; Liming Guan; Kara S Punt; Aimin Tang; Minchun Chen; Keith A Wilson; Kelly B Collins; Gwendolyn J Heidecker; V Rose Fernandez; Helen C Perry; Joseph G Joyce; Karen M Grimm; James C Cook; Paul M Keller; Denise S Kresock; Henryk Mach; Robert D Troutman; Lynne A Isopi; Donna M Williams; Zheng Xu; Kathryn E Bohannon; David B Volkin; David C Montefiori; Ayako Miura; Georgia R Krivulka; Michelle A Lifton; Marcelo J Kuroda; Jörn E Schmitz; Norman L Letvin; Michael J Caulfield; Andrew J Bett; Rima Youil; David C Kaslow; Emilio A Emini
Journal:  Nature       Date:  2002-01-17       Impact factor: 49.962

5.  A phase I trial of preventive HIV vaccination with heterologous poxviral-vectors containing matching HIV-1 inserts in healthy HIV-uninfected subjects.

Authors:  Michael C Keefer; Sharon E Frey; Marnie Elizaga; Barbara Metch; Stephen C De Rosa; Paulo F Barroso; Georgia Tomaras; Massimo Cardinali; Paul Goepfert; Artur Kalichman; Valérie Philippon; M Juliana McElrath; Xia Jin; Guido Ferrari; Olivier D Defawe; Gail P Mazzara; David Montefiori; Michael Pensiero; Dennis L Panicali; Lawrence Corey
Journal:  Vaccine       Date:  2011-01-07       Impact factor: 3.641

6.  Randomized, double-blind, placebo-controlled efficacy trial of a bivalent recombinant glycoprotein 120 HIV-1 vaccine among injection drug users in Bangkok, Thailand.

Authors:  Punnee Pitisuttithum; Peter Gilbert; Marc Gurwith; William Heyward; Michael Martin; Fritz van Griensven; Dale Hu; Jordan W Tappero; Kachit Choopanya
Journal:  J Infect Dis       Date:  2006-11-03       Impact factor: 5.226

7.  A study of the vaccinia virus interferon-gamma receptor and its contribution to virus virulence.

Authors:  Julian A Symons; David C Tscharke; Nicola Price; Geoffrey L Smith
Journal:  J Gen Virol       Date:  2002-08       Impact factor: 3.891

8.  Phase 1 safety and immunogenicity evaluation of ADMVA, a multigenic, modified vaccinia Ankara-HIV-1 B'/C candidate vaccine.

Authors:  Sandhya Vasan; Sarah J Schlesinger; Zhiwei Chen; Arlene Hurley; Angela Lombardo; Soe Than; Phumla Adesanya; Catherine Bunce; Mark Boaz; Rosanne Boyle; Eddy Sayeed; Lorna Clark; Daniel Dugin; Mar Boente-Carrera; Claudia Schmidt; Qing Fang; Yaoxing Huang; Gerasimos J Zaharatos; David F Gardiner; Marina Caskey; Laura Seamons; Martin Ho; Len Dally; Carol Smith; Josephine Cox; Dilbinder Gill; Jill Gilmour; Michael C Keefer; Patricia Fast; David D Ho
Journal:  PLoS One       Date:  2010-01-25       Impact factor: 3.240

9.  Phase 1 evaluation of 3 highly immunogenic prime-boost regimens, including a 12-month reboosting vaccination, for malaria vaccination in Gambian men.

Authors:  Vasee S Moorthy; Egeruan B Imoukhuede; Sheila Keating; Margaret Pinder; Daniel Webster; Michael A Skinner; Sarah C Gilbert; Gijs Walraven; Adrian V S Hill
Journal:  J Infect Dis       Date:  2004-05-24       Impact factor: 5.226

10.  Extended follow-up following a phase 2b randomized trial of the candidate malaria vaccines FP9 ME-TRAP and MVA ME-TRAP among children in Kenya.

Authors:  Philip Bejon; Edna Ogada; Tabitha Mwangi; Paul Milligan; Trudie Lang; Greg Fegan; Sarah C Gilbert; Norbert Peshu; Kevin Marsh; Adrian V S Hill
Journal:  PLoS One       Date:  2007-08-15       Impact factor: 3.240

View more
  23 in total

Review 1.  Enhancing poxvirus vectors vaccine immunogenicity.

Authors:  Juan García-Arriaza; Mariano Esteban
Journal:  Hum Vaccin Immunother       Date:  2014       Impact factor: 3.452

Review 2.  Immunogenicity and efficacy of DNA/MVA HIV vaccines in rhesus macaque models.

Authors:  Lynette Siv Chea; Rama Rao Amara
Journal:  Expert Rev Vaccines       Date:  2017-09-04       Impact factor: 5.217

3.  Deletion of the vaccinia virus N2L gene encoding an inhibitor of IRF3 improves the immunogenicity of modified vaccinia virus Ankara expressing HIV-1 antigens.

Authors:  Juan García-Arriaza; Carmen E Gómez; Carlos Óscar S Sorzano; Mariano Esteban
Journal:  J Virol       Date:  2014-01-03       Impact factor: 5.103

4.  Clade C HIV-1 Envelope Vaccination Regimens Differ in Their Ability To Elicit Antibodies with Moderate Neutralization Breadth against Genetically Diverse Tier 2 HIV-1 Envelope Variants.

Authors:  Samantha Burton; Lori M Spicer; Tysheena P Charles; Sailaja Gangadhara; Pradeep B J Reddy; Tiffany M Styles; Vijayakumar Velu; Sudhir Pai Kasturi; Traci Legere; Eric Hunter; Bali Pulendran; Rama Amara; Peter Hraber; Cynthia A Derdeyn
Journal:  J Virol       Date:  2019-03-21       Impact factor: 5.103

5.  Deletion of Fifteen Open Reading Frames from Modified Vaccinia Virus Ankara Fails to Improve Immunogenicity.

Authors:  Naif Khalaf Alharbi; Alexandra J Spencer; Adrian V S Hill; Sarah C Gilbert
Journal:  PLoS One       Date:  2015-06-08       Impact factor: 3.240

6.  Novel Modified Vaccinia Virus Ankara Vector Expressing Anti-apoptotic Gene B13R Delays Apoptosis and Enhances Humoral Responses.

Authors:  Lynette S Chea; Linda S Wyatt; Sailaja Gangadhara; Bernard Moss; Rama R Amara
Journal:  J Virol       Date:  2019-02-19       Impact factor: 5.103

7.  Virological and immunological characterization of novel NYVAC-based HIV/AIDS vaccine candidates expressing clade C trimeric soluble gp140(ZM96) and Gag(ZM96)-Pol-Nef(CN54) as virus-like particles.

Authors:  Beatriz Perdiguero; Carmen Elena Gómez; Victoria Cepeda; Lucas Sánchez-Sampedro; Juan García-Arriaza; Ernesto Mejías-Pérez; Victoria Jiménez; Cristina Sánchez; Carlos Óscar S Sorzano; Juan Carlos Oliveros; Julie Delaloye; Thierry Roger; Thierry Calandra; Benedikt Asbach; Ralf Wagner; Karen V Kibler; Bertram L Jacobs; Giuseppe Pantaleo; Mariano Esteban
Journal:  J Virol       Date:  2014-10-29       Impact factor: 5.103

8.  Optimized Mucosal Modified Vaccinia Virus Ankara Prime/Soluble gp120 Boost HIV Vaccination Regimen Induces Antibody Responses Similar to Those of an Intramuscular Regimen.

Authors:  Dorothy I Jones; Justin J Pollara; Brandi T Johnson-Weaver; Celia C LaBranche; David C Montefiori; David J Pickup; Sallie R Permar; Soman N Abraham; Massimo Maddaloni; David W Pascual; Herman F Staats
Journal:  J Virol       Date:  2019-06-28       Impact factor: 5.103

9.  Attenuation and immunogenicity of host-range extended modified vaccinia virus Ankara recombinants.

Authors:  Sharon Melamed; Linda S Wyatt; Robin J Kastenmayer; Bernard Moss
Journal:  Vaccine       Date:  2013-08-06       Impact factor: 3.641

10.  Improving Adaptive and Memory Immune Responses of an HIV/AIDS Vaccine Candidate MVA-B by Deletion of Vaccinia Virus Genes (C6L and K7R) Blocking Interferon Signaling Pathways.

Authors:  Juan García-Arriaza; Pilar Arnáez; Carmen E Gómez; Carlos Óscar S Sorzano; Mariano Esteban
Journal:  PLoS One       Date:  2013-06-27       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.